Company / Return on Equity (ROE)
Ernexa Therapeutics Inc. Return on Equity (ROE) History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-2618.4%
FY2025
5-year range
-2618.4% / -3.7%
FY2021-FY2025
Trend
-169.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Ernexa Therapeutics Inc. reports negative total equity of -2618.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-2618.4% in FY2025 with a 10-year CAGR of -2572.4%.
Declined from -203.0% to -2618.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -2578.2pp
- 10-Year Change
- -2572.4pp
Key checks
Key Insights
- Ernexa Therapeutics Inc.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 169.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2618.4% | -169.8% |
| FY2024 | -970.4% | -378.0% |
| FY2023 | -203.0% | -404.9% |
| FY2020 | -40.2% | -975.1% |
| FY2019 | -3.7% | +80.8% |
| FY2018 | -19.4% | +72.9% |
| FY2017 | -71.9% | +61.7% |
| FY2016 | -187.8% | -307.8% |
| FY2015 | -46.1% | -302.5% |
| FY2014 | -11.4% | +9.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026